Successful Management of a Rare Cause of Hemolytic Uremic Syndrome With Eculizumab in a Child
Conclusion:
In conclusion, eculizumab may be a treatment of choice to prevent further systemic damage in recurrent HUS episodes of patients with borderline changes in the bone marrow until ALL is constantly diagnosed.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Clinical and Laboratory Observations Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Anemia | Brain | Cancer & Oncology | Children | Dialysis | Hematology | Hemodialysis | Hemolytic Uremic Syndrome (HUS) | Laboratory Medicine | Leukemia | Microangiopathic Hemolytic Anemia | Neurology | Pain | Pain Management | Pancytopenia | Pediatrics | Renal Failure | Thrombocytopenia